Meet the robot that draws blood better than humans

In the near future, patients may have their blood drawn and tested by an advanced robot—and it’s a move that would benefit both patients and healthcare providers.

Researchers created and tested the robot, publishing their findings in Technology.

“Obtaining venous access for blood sampling or intravenous fluid delivery is an essential first step in patient care,” wrote lead author Josh Leipheimer, a biomedical engineering student at Rutgers University-New Brunswick, and colleagues. “However, success rates rely heavily on clinician experience and patient physiology. Difficulties in obtaining venous access result in missed sticks and injury to patients, and typically require alternative access pathways and additional personnel that lengthen procedure times, thereby creating unnecessary costs to healthcare facilities.”

The device uses ultrasound imaging to locate and draw blood from the patient’s veins. It can also handle blood samples once they have been drawn.

Leipheimer and colleagues found that their robot performed these tasks as well, or even better, than a human healthcare provider. It had an overall success rate of 87% and a success rate of 97% for “nondifficult venous access.”

The team sees a future when ambulances, emergency rooms and hospitals all embrace this technology.

“A device like ours could help clinicians get blood samples quickly, safely and reliably, preventing unnecessary complications and pain in patients from multiple needle insertion attempts,” Leipheimer said in a prepared statement.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.